City
Epaper

Government has recovered Rs 72.73 cr from drug manufacturers for selling drugs at higher prices

By ANI | Updated: July 30, 2024 15:40 IST

New Delhi [India] July 30 : The central government has taken action against companies found selling formulations at prices ...

Open in App

New Delhi [India] July 30 : The central government has taken action against companies found selling formulations at prices higher than the permissible price. In the year 2023-24, it has recovered Rs 72.73 crore from the defaulting companies who have overcharged the consumers, Union Minister of State for Chemicals and Fertilizers Anupriya Patel informed Rajya Sabha on Tuesday in reply to a question.

As per the provisions of the Drug Prices Control (DPCO), 2013, the ceiling prices of scheduled medicines are revised annually on the basis of the Wholesale Price Index (WPI) for the preceding calendar year by National Pharmaceutical Pricing Authority (NPPA), on or before 1st April of every year. The government notifies the revised prices on April 1st every year.

The details of the price fixed by NPPA are made available at NPPA's website. Both schedule and non-schedule drugs are covered under DPCO, 2013.

In case of non-scheduled formulation (branded or generic), as per DPCO, 2013, no manufacturer can increase Maximum Retail Price (MRP) by more than 10 per cent of MRP during the preceding 12 months.

However, the manufacturer may choose not to increase the prices for scheduled and non-scheduled drugs based on commercial considerations and market dynamics.

Formulations listed in Schedule-I of the DPCO are defined as scheduled formulations, while formulations not included in Schedule -I are defined as non-scheduled formulations.

Under the Drugs and Cosmetics Act, 1945, manufacturers of drugs are required to comply with the conditions of the manufacturing license and the requirements of Good Manufacturing Practices.

The manufacturing, testing, labelling, packaging, storage, and distribution are required to be carried out in compliance with the conditions of the license including the Good Manufacturing Practices prescribed under Drugs Rules. In case of violation, the Licensing Authority is empowered to take action as per the said Act and Rules.

NPPA monitors the prices of scheduled as well as non-scheduled medicines.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in App

Related Stories

Technology350 AI datasets uploaded on AI Kosh, 4 AI tools developed by IITs: Minister

Other SportsPalace beat Villa 3-0 to enter FA Cup final

Business350 AI datasets uploaded on AI Kosh, 4 AI tools developed by IITs: Minister

NationalPak media highlights CM Siddaramaiah’s 'no war' remarks, K'taka BJP says 'puppet of enemy nation'

EntertainmentNawazuddin Siddiqui reveals what drew him to play a fearless customs officer in ‘Costao’

Business Realted Stories

BusinessIndian goods worth over USD 10 billion reach pakistan via third-country routes: GTRI

BusinessMahindra to acquire 58.96% stake in SML Isuzu for Rs 555 crore

BusinessCentre launches portal, guidelines for electronics component manufacturing scheme; aims for large investments

BusinessMillions benefited from Ayushman health cards, now is the time for Delhi: Hardeep Puri

BusinessViksit Bharat will be driven by start-ups and innovation: IIT Madras Director